Hodgkin Lymphoma
Conditions
Keywords
MOAP; Relapsed/Refractory; Hodgkin Lymphoma; DP;
Brief summary
The DP regimen, low-dose decitabine combined with SHR-1210, is the new treatment for relapsed or refractory classical Hodgkin's Lymphoma. Though the CR rate of this regimen is impressively high, which is verified more than 70% in our I/II phase study, there are also lots of patients cannot benefit from this treatment. On top of that, as the increasing utilization of mono-therapy or combination treatment with the immune checkpoint blockade (ICB), the adverse reactions associated with immunotherapy make it unavailable in parts of patients. The application of MOAP regimen to patients, who have a progressive disease after DP regimen, can bring high CR rate. MOAP can be the a rescue treatment for cHL resisted to DP treatment.
Interventions
DRUGMOAP
the new chemotherapy regimen for r/r cHL
Sponsors
Han weidong
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
13 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
1. Subjects must have histological confirmation of relapsed or refractory Hodgkin lymphoma (HL). 2. 13 to 70 years of age. 3. ECOG performance of less than 2. 4. Life expectancy of at least 3 months. 5. Subjects with lymphoma must have at least one measureable lesion \>1 cm as defined by lymphoma response criteria. 6. Subjects must have received at least two prior chemotherapy regimen and four cycle of DP regimen, and must be off therapy for at least 4 weeks prior to Day 1. Subjects with autologous hematopoietic stem-cell transplantation are eligible which must be more than 3 months. 7. Subjects must have adequate marrow, live, renal and heart functions.
Exclusion criteria
1. Subjects with any autoimmune disease or history of syndrome that requires corticosteroids or immunosuppressive medications. 2. Serious uncontrolled medical disorders or active infections, pulmonary infection especially. 3. Active alimentary tract hemorrhage or history of alimentary tract hemorrhage in 1 month . 4. Prior organ allograft. 5. Women who are pregnant or breastfeeding. 6. Women with a positive pregnancy test on enrollment or prior to investigational product administration. 7. Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CRR assess by investigators per the 2014 Lugano classification | 3 years | Time measured from the day of first documented PR or CR to the date of first rate of subjects achieved complete response in all evaluable subjects |
| Number of Subjects with treatment-related adverse events (AEs) | 2 years | Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v4.03. |
| duration of CR | 5 years | Time measured from the day of first documented CR to the date of first documented progression, or death from any cause. |
Countries
China
Contacts
Primary ContactWeidong Han
Outcome results
None listed